Pitch Challenge 2021 Contestant George Foulard, MD, Discusses Platform for Hospital Capacity Management
George Foulard, MD, a Diagnostic Radiology Resident at The Mount Sinai Hospital, is presenting Bedboard at the Mount Sinai Pitch Challenge on May 5. Bedboard, an information technology platform that matches discharged or transferred patients with proper care settings, won the Innovation …
Mount Sinai Venture Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021
Kantaro Biosciences among top-ranked in the Joint Venture category Mount Sinai Health System announced today that Kantaro Biosciences, LLC, a joint venture with RenalytixAI, has been named to Fast Company’s prestigious annual list of the “World’s Most Innovative Companies” for 2021 and …
Vaxalto Biotherapeutics and Mount Sinai Enter into Exclusive License Agreement for the Development and Commercialization of Novel Immunotherapeutic Oncolytic Viruses for Treatment of Cancer
Vaxalto Biotherapeutics, Inc. (www.vaxalto.com), a pre-clinical stage biotechnology company focused on developing and commercializing novel engineered immunotherapeutic oncolytic viruses, and Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, have partnered to develop novel cancer immunotherapies. Mount Sinai has …
FDA Adds Kantaro’s Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma
COVID-SeroKlir is a high-performance test that detects the presence and precise level of SARS-CoV-2 IgG antibodies NEW YORK, Feb. 10, 2021 — Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX /NASDAQ: RNLX), and manufacturing partner …
Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America
Kantaro’s COVID-SeroKlir and COVID-SeroIndex are high-performing tests that detect the presence and precise level of neutralizing antibodies¹ First and only quantitative COVID-19 antibody tests that do not require proprietary equipment NEW YORK, Feb. 8, 2021 — Kantaro Biosciences, LLC, a joint venture …
Robert J. Desnick , MD, E. Premkumar Reddy, PhD, and Edward Schuchman, PhD, Elected to the National Academy of Inventors
Mount Sinai researchers Robert J. Desnick, MD, PhD, E. Premkumar (Prem) Reddy, PhD, and Edward Schuchman, PhD, became Fellows of the National Academy of Inventors (NAI). The National Academy of Inventors (NAI) is a prestigious organization, comprised of international universities, and governmental …
MSIP Honors Inventors for their Exemplary Work in Developing Mount Sinai’s COVID-19 Antibody Test
At the Innovation Awards Ceremony on December 8, Mount Sinai Innovation Partners (MSIP) presented the award for Inventor of the Year to eight individuals whose efforts led to the development of multiple diagnostic tests for the detection of antibodies against the COVID-19 …
Next-gen antibody tests promise more answers to Covid-19 questions
MedCity News The new tests can open a window into the duration of immunity and to the antibody levels needed to sustain it. But first, a universal standard is needed to ensure results are comparable between tests. The next generation of antibody …
FDA clears a ‘new generation’ of Covid antibody test designed to tell how well someone is protected against the virus
CNBC — Wednesday, November 25, 2020 The FDA on Wednesday authorized one of the first Covid-19 tests that measures the amount of neutralizing antibodies produced by the body’s immune system after exposure to the virus — a “new generation” of coronavirus test that …